In premenopausal breast cancer patients with advanced disease, reduction of estrogen levels by a GnRH agonist in combination with the ER antagonist tamoxifen improves clinical outcome compared with the use of GnRH agonists or tamoxifen alone [29,30]. This evidence concerns the gene GNRH1 and breast carcinoma.